CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $2.67B, above the global median of $548.88M
- PositionDebt-to-equity is 1.73×, higher than 95% of its Medical Devices peers (median 0.11×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
750.22MUSDvs all stocks (USD)
Revenue (TTM)
2.67BUSDvs all stocks (USD)
Profit Margin
-39.20%vs Medical Devices peers
Beta
0.6760xvs all stocks
52-Week Change
-62.12%vs all stocks
Market Capitalization
750.22MUSDvs all stocks (USD)
Enterprise Value
3.70BUSDvs all stocks (USD)
Forward P/E
7.59xvs Medical Devices peers
Price to Sales (TTM)
0.2805xvs Medical Devices peers
Price to Book (MRQ)
0.4210xvs Medical Devices peers
Enterprise to Revenue
1.38xvs Medical Devices peers
Enterprise to EBITDA
7.64xvs Medical Devices peers
Gross Margin
43.26%vs Medical Devices peers
Profit Margin
-39.20%vs Medical Devices peers
Operating Margin
-2.09%vs Medical Devices peers
Return on Assets (TTM)
0.38%vs Medical Devices peers
Return on Equity (TTM)
-45.91%vs Medical Devices peers
Revenue (TTM)
2.67BUSDvs all stocks (USD)
Revenue per Share (TTM)
39.27USDUpdated Sep 28, 2026Quarterly Revenue Growth
2.80%vs Medical Devices peers
Gross Profit (TTM)
1.20BUSDvs all stocks (USD)
EBITDA (TTM)
417.10MUSDvs all stocks (USD)
Net Income (TTM)
-1.05BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
2.77%vs Medical Devices peers
Operating Cash Flow (TTM)
-57.20MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
2.73BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.46BUSDFY2025 · Dec 31, 2025Gross Profit
1.27BUSDFY2025 · Dec 31, 2025Operating Income
54.80MUSDvs all stocks (USD)
Pre-tax Income
-1.11BUSDFY2025 · Dec 31, 2025Income Tax Expense
24.10MUSDFY2025 · Dec 31, 2025Net Income
-1.13BUSDFY2025 · Dec 31, 2025EBIT
-924.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
488.50MUSDFY2025 · Dec 31, 2025Research & Development
186.20MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
746.30MUSDFY2025 · Dec 31, 2025Other Operating Expenses
97.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
183.10MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-1.13BUSDFY2025 · Dec 31, 2025Operating Cash Flow
-770.50MUSDFY2025 · Dec 31, 2025Free Cash Flow
-958.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
169.80MUSDFY2025 · Dec 31, 2025Interest Paid
172.40MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.13BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
442.00MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
6.30MUSDFY2025 · Dec 31, 2025Stock-based Compensation
45.90MUSDFY2025 · Dec 31, 2025Other Non-cash Items
900.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-117.50MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
40.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-56.30MUSDFY2025 · Dec 31, 2025Capital Expenditures
-188.20MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Other Investing Activity
-4.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-192.70MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
2.56BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-2.41BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
3.00MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-5.40MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
155.80MUSDFY2025 · Dec 31, 2025Shares Outstanding
68.30MSharesUpdated Sep 28, 2026Float Shares
61.17MSharesUpdated Sep 28, 2026Shares Short
14.19MSharesUpdated Sep 28, 2026Short Ratio
10.45daysvs all stocks
Short % of Shares Outstanding
28.21%vs all stocks
% Held by Insiders
0.90%vs all stocks
% Held by Institutions
124.20%vs all stocks
Total Cash (MRQ)
123.40MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.80USDUpdated Sep 28, 2026Total Debt (MRQ)
3.08BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.73xvs Medical Devices peers
Current Ratio (MRQ)
1.39xvs Medical Devices peers
Book Value per Share (MRQ)
25.99USDUpdated Sep 28, 2026Total Assets
5.77BUSDvs all stocks (USD)
Total Current Assets
1.45BUSDFY2025 · Dec 31, 2025Total Liabilities
3.85BUSDFY2025 · Dec 31, 2025Total Non-current Assets
4.32BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.88BUSDFY2025 · Dec 31, 2025Total Current Liabilities
966.10MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
169.80MUSDFY2025 · Dec 31, 2025Accounts Receivable
417.00MUSDFY2025 · Dec 31, 2025Inventory
577.60MUSDFY2025 · Dec 31, 2025Accounts Payable
279.40MUSDFY2025 · Dec 31, 2025Short-term Debt
207.60MUSDFY2025 · Dec 31, 2025Deferred Revenue
37.80MUSDFY2025 · Dec 31, 2025Other Current Liabilities
164.30MUSDFY2025 · Dec 31, 2025Long-term Debt
2.63BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
166.40MUSDFY2025 · Dec 31, 2025Common Stock (Book)
100.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-996.00MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.92BUSDvs all stocks (USD)
52-Week Low
9.92USDUpdated Sep 28, 202652-Week High
35.58USDUpdated Sep 28, 202652-Week Change
-62.12%vs all stocks
Beta
0.6760xvs all stocks
50-Day MA
14.35USDUpdated Sep 28, 2026200-Day MA
18.52USDUpdated Sep 28, 2026Avg 10-Day Volume
1.81MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.39MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-15.43USDUpdated Sep 28, 2026Other Income / Expense
-976.90MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.73×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 1.73Industry median: 0.11Industry P95: 1.28Peers compared: 102
Price-to-book is 0.42×, lower than 95% of its Medical Devices peers (median 2.51×)Notable
Price-to-book: 0.42Industry median: 2.51Industry P5: 0.60Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.43Profit Margin: -0.39
Financial Health
Altman Z-Score -0.08: distress zoneCritical
Altman Z-Score: -0.08
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $2.67B, above the global median of $548.88MNotable
Revenue (USD): 2,674,200,064Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Olema Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Md Entertainment Tbk
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Beijing Xiaocheng Technology Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated